BR112019007564A2 - composições dispersíveis - Google Patents

composições dispersíveis

Info

Publication number
BR112019007564A2
BR112019007564A2 BR112019007564A BR112019007564A BR112019007564A2 BR 112019007564 A2 BR112019007564 A2 BR 112019007564A2 BR 112019007564 A BR112019007564 A BR 112019007564A BR 112019007564 A BR112019007564 A BR 112019007564A BR 112019007564 A2 BR112019007564 A2 BR 112019007564A2
Authority
BR
Brazil
Prior art keywords
compositions
useful
dispersible compositions
dispersible
rilpivirine
Prior art date
Application number
BR112019007564A
Other languages
English (en)
Inventor
Patankar Harshad
Martha Felix Goyvaerts Nicolaas
Rajan Ranga Rajan Gopal
Original Assignee
Janssen Sciences Ireland Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Company filed Critical Janssen Sciences Ireland Unlimited Company
Publication of BR112019007564A2 publication Critical patent/BR112019007564A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
  • Cosmetics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

a presente invenção diz respeito a composições dispersíveis compreendendo rilpivirina ou um seu sal de adição de ácidos farmaceuticamente aceitável como um ingrediente ativo. tais composições são úteis no tratamento de infecção pelo hiv e suas propriedades de dispersibilidade se prestam a ser úteis em particular entre a população pediátrica ou geriátrica.
BR112019007564A 2016-10-24 2017-10-23 composições dispersíveis BR112019007564A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
PCT/EP2017/077030 WO2018077815A1 (en) 2016-10-24 2017-10-23 Dispersible compositions

Publications (1)

Publication Number Publication Date
BR112019007564A2 true BR112019007564A2 (pt) 2019-07-02

Family

ID=60262899

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007564A BR112019007564A2 (pt) 2016-10-24 2017-10-23 composições dispersíveis

Country Status (21)

Country Link
US (2) US11065198B2 (pt)
EP (2) EP4248947A3 (pt)
JP (2) JP7197474B2 (pt)
KR (2) KR20240011873A (pt)
CN (1) CN110191704A (pt)
BR (1) BR112019007564A2 (pt)
CA (1) CA3039562A1 (pt)
DK (1) DK3528791T3 (pt)
FI (1) FI3528791T3 (pt)
HR (1) HRP20240118T1 (pt)
HU (1) HUE064823T2 (pt)
LT (1) LT3528791T (pt)
MA (1) MA46563B1 (pt)
MX (1) MX2019004767A (pt)
PL (1) PL3528791T3 (pt)
PT (1) PT3528791T (pt)
RS (1) RS65159B1 (pt)
RU (1) RU2019115672A (pt)
SI (1) SI3528791T1 (pt)
TW (1) TWI821163B (pt)
WO (1) WO2018077815A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020391004A1 (en) 2019-11-29 2022-04-07 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (en) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Compression-coated dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
KR101140785B1 (ko) 2002-08-09 2012-05-03 얀센 파마슈티카 엔.브이. 4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
KR101284361B1 (ko) 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
SG155885A1 (en) * 2004-09-02 2009-10-29 Janssen Pharmaceutica Nv Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
ATE508748T1 (de) * 2004-09-02 2011-05-15 Janssen Pharmaceutica Nv Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril.
AU2007262941B2 (en) 2006-06-23 2013-11-21 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
US20160346198A1 (en) * 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015136294A1 (en) * 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine
BR112016026667A8 (pt) * 2014-05-16 2021-07-06 Vivus Inc comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v

Also Published As

Publication number Publication date
RS65159B1 (sr) 2024-02-29
KR20240011873A (ko) 2024-01-26
EP4248947A3 (en) 2023-11-22
EP4248947A2 (en) 2023-09-27
JP2023011659A (ja) 2023-01-24
US11065198B2 (en) 2021-07-20
CN110191704A (zh) 2019-08-30
HUE064823T2 (hu) 2024-04-28
PL3528791T3 (pl) 2024-04-02
JP2020500168A (ja) 2020-01-09
EP3528791A1 (en) 2019-08-28
US20220008333A1 (en) 2022-01-13
EP3528791B1 (en) 2023-12-06
TW201828927A (zh) 2018-08-16
MA46563B1 (fr) 2024-01-31
CA3039562A1 (en) 2018-05-03
MX2019004767A (es) 2019-07-01
KR20190073450A (ko) 2019-06-26
HRP20240118T1 (hr) 2024-04-12
TWI821163B (zh) 2023-11-11
JP7197474B2 (ja) 2022-12-27
WO2018077815A1 (en) 2018-05-03
SI3528791T1 (sl) 2024-04-30
RU2019115672A3 (pt) 2021-01-21
DK3528791T3 (da) 2024-01-29
PT3528791T (pt) 2024-02-19
LT3528791T (lt) 2024-05-27
RU2019115672A (ru) 2020-11-24
MA46563A (fr) 2019-08-28
US20200069579A1 (en) 2020-03-05
FI3528791T3 (fi) 2024-01-30

Similar Documents

Publication Publication Date Title
CY1124592T1 (el) Ζιζανιοκτονως δραστικα 3-φαινυλοïσοξαζολινο-5-καρβοξαμιδια αποτελουμενα απο τετραϋδρο- και διυδροφουρανοκαρβοξυλικα οξεα και εστερες
NZ733174A (en) Quinazoline derivatives used to treat hiv
AU2018285213A1 (en) Herbicidally active 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxamides
EA201890425A1 (ru) Противовирусные фосфодиамидные сложноэфирные бета-аминокислотные соединения
PH12017501331A1 (en) Dispersible compositions
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
MD4577B1 (ro) Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare
BR112019007564A2 (pt) composições dispersíveis
BR112014008255A2 (pt) composições antimicrobianas e métodos empregando as mesmas
CU24525B1 (es) Derivado de quinoleína para tratar y prevenir infecciones virales
EP3757105A3 (en) Polycyclic pyridone derivative having integrase inhibitory activity
BR112016016854A2 (pt) Derivados de 7-oxo-1,6-diazabiciclo[3.2.1]octana, seu processo de preparação e seu uso, composição farmacêutica e seu uso pedidos de patente relacionados
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
BR112020020708A8 (pt) Derivados da ureia cíclica fundidã como antagonista crhr2
BR112019020228A2 (pt) Formulações de alcalóide berberina na prevenção e/ou tratamento de doenças infecciosas
MX2019006768A (es) Peptidos antimicrobianos.
MX2018010264A (es) Formulaciones libres de solventes de sustancias activas de bajo punto de fusion.
MX2018011095A (es) Compuestos de carbapenem.
BR112019007631A2 (pt) inibidores de bromodomínios
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112018002678A2 (pt) composto, composição, e, método para tratar infecção por hiv
TR201910158T4 (tr) İmmün hastalıklara yönelik önleyici ve/veya terapötik ajan.
WO2015102850A3 (en) Compositions, devices and methods for treating infections
BR112017013545A2 (pt) composto de tiotriazol e seu uso em infecções por protozoários parasíticos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]